Search

Displaying results 671 - 680 of 3917 in total
  1. Drug

    Tenapanor

    go.drugbank.com/drugs/DB11761
    ApprovedInvestigational

    Tenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C). It was first designed and synthesized in 2012. As an inhibitor of the sodium/hydro...

  2. Drug

    Sunvozertinib

    go.drugbank.com/drugs/DB18925
    Investigational

    [A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor … [L53488] EGFR is a transmembrane protein with cytoplasmic kinase activity commonly expressed by non-small cell lung carcinomas (NSCLCs).

  3. Drug

    Ancestim

    go.drugbank.com/drugs/DB09103
    ApprovedWithdrawn

    Ancestim is a non-glycosylated recombinant methionyl human stem cell factor.

  4. Drug

    Tropicamide

    go.drugbank.com/drugs/DB00809
    Approved

    Tropicamide is an alkaloid atropine‐derived anticholinergic drug and a non‐selective antagonist of muscarinic acetylcholine (mACh) receptors.

  5. Drug

    Formebolone

    go.drugbank.com/drugs/DB01569
    IllicitInvestigational

    It has been used experimentally in the treatment of growth retardation, and has been noted to increase bone mass. … It is on the list of substances prohibited by the Word Anti-Doping Agency, and is regularly screened for in athletes.

  6. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    [L14336] This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials … [A214331] On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression

  7. Drug

    Tyrothricin

    go.drugbank.com/drugs/DB13503
    ApprovedWithdrawn

    Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus Brevibacillus parabrevis which was previously categorized as Bacillus brevis and Bacillus aneurinolyticus . This complex is a mix...

  8. Drug

    Dexamethasone

    go.drugbank.com/drugs/DB01234
    ApprovedInvestigationalVet approved

    [A188724] Dexamethasone was granted FDA approval on 30 October 1958. … [L10695] In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms

  9. Drug

    Odronextamab

    go.drugbank.com/drugs/DB16684
    ApprovedInvestigational

    Odronextamab is a hinge-stabilized, fully human immunoglobulin G4 (IgG4)-based CD20×CD3 bispecific antibody currently evaluated for the treatment of relapsed/refractory (R/R) B-Cell non-Hodgkin lymphoma … [L43887,L43892] A phase I clinical study (NCT02290951) showed that in heavily pre-treated patients with B-cell non-Hodgkin lymphoma, odronextamab elicited a durable response with a manageable safety

  10. Drug

    Penbutolol

    go.drugbank.com/drugs/DB01359
    ApprovedInvestigationalWithdrawn

    Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker.

    Categories: Beta Blocking Agents, Non-Selective